Jan 4 (Reuters) - A federal judge on Wednesday said Botox maker AbbVie's ABBV.N Allergan unit can move ahead with its lawsuit accusing Revance Therapeutics RVNC.O of taking its confidential data to ...

Migraine episodes are tough, but the women who fight through them are tougher. That’s the message from Allergan in its evolved Botox for chronic migraine marketing. New TV ads, first begun in the fall ...

For Allergan Inc., a subtle offense has proved the best defense in the court of public opinion over Botox. Observers give the Irvine drug maker good marks for its strategy in support of Allergan’s ...

Deciding whether to get Botox can feel confusing, especially when marketing claims and results don't always match. That is ...

CHICAGO (Reuters) - Allergan Inc said on Thursday that its popular Botox facial wrinkle-smoother worked as a treatment for adults suffering from chronic migraines, according to late-stage clinical ...

Botox, used for smoothing out wrinkles, is the number one selling neurotoxin globally Allergan Aesthetics’ main product Botox received Food and Drug Administration approval for a new indication in ...

When patients come into the Palo Alto, CA, offices of facial plastic surgeons Drs. David M. Lieberman, MD, and Sachin S. Parikh, MD, they aren’t necessarily concerned with the authenticity of their ...

Pharmaceutical giant Allergan will pay $600 million to settle civil and criminal accusations that it illegally marketed Botox for uses for which the drug had not been approved. The settlement with the ...

Shares of Allergan plc Ordinary Shares AGN continue trading near their multi year low of $160.07, with many investors concerned with a competitive environment that will intensify in the coming years.

The anti-wrinkle drug Botox dramatically lifted Allergan Inc.’s first-quarter earnings but couldn’t smooth out Wall Street’s concerns about the rest of the year. Allergan said Monday that quarterly ...

For the second time in less than a year, the Food and Drug Administration has warned Irvine-based Allergan Inc. that advertisements for its anti-wrinkle drug Botox are misleading and should be pulled.

The drugmaker AbbVie said Tuesday that it planned to buy Allergan, the maker of Botox, for about $63 billion in one of the biggest mergers in the health care industry this year. If completed, the deal ...